 |
|
|
|
 |
|
|
Tazobactam
|
|
Tazobactam
|
| Systematic (IUPAC) name |
| (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-
(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid
|
| Identifiers |
| CAS number |
89786-04-9 |
| ATC code |
J01CG02 |
| PubChem |
? |
| DrugBank |
EXPT03012 |
| Chemical data |
| Formula |
C10H12N4O5S |
| Mol. mass |
300.289 g/mol |
| Pharmacokinetic data |
| Bioavailability |
? |
| Metabolism |
? |
| Half life |
? |
| Excretion |
? |
| Therapeutic considerations |
| Pregnancy cat. |
?
|
| Legal status |
|
| Routes |
? |
Tazobactam is a compound which inhibits the action of bacterial beta-lactamases. It is added to the extended spectrum beta-lactam antibiotic piperacillin to produce Tazocin® or Zosyn®. It broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade piperacillin.
Tazobactam sodium is a derivative of the penicillin nucleus and is a penicillanic acid sulfone.
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tazobactam". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top